南京融捷康

Nanjing Rongjiekang is a clinical-stage biotechnology company specializing in the discovery and development of nanobody-based therapeutics. The company leverages its proprietary camelid-derived single-domain antibody (VHH) platform to engineer drugs with superior stability, high affinity, and enhanced tissue penetration compared to traditional antibodies. Its lead program, RJ001, is a PD-L1-targeting nanobody currently undergoing clinical evaluation for advanced solid tumors. With a robust pipeline targeting immune checkpoints and tumor-associated antigens like CD47 and Claudin 18.2, Rongjiekang aims to address significant unmet needs in oncology through innovative immunotherapy. The company's technology platform also supports the development of multi-specific antibodies and drug conjugates designed for complex disease environments.